Record overview
Status and phase
Status: TERMINATED
Phase: PHASE1, PHASE2
Sponsor: GlaxoSmithKline
Condition: Relapsed/Refractory Multiple Myeloma
NCT06655818
Sub-study of Belantamab Mafodotin (GSK2857916) as Monotherapy and in Combination With Dostarlimab (GSK4057190) in Participants With RRMM
Public trial-level signal summary for this oncology Phase 2 record.
Signal summary
Public flags
Status signal: Registry Stop Signal
Timeline signals: stale_update_signal
Results signal: Low Signal
Operational burden: rare_population_signal | strict_eligibility_signal | complex_intervention_signal
Stopped reason
Context when available
The study was terminated due to lack of efficacy